Abstract 85P
Background
Treatment recommendations and benefit of local therapy in oligometastatic disease (OMD) are an era of interest and debate; however, it’s quite difficult to plan RCTs including patients with metastases due to ethical considerations as patients may lose an effective treatment if they are assigned to a control arm, furthermore, most of the clinical literature on OMD is cancer site specific, this study included OMD of different solid tumors.
Methods
In this observational prospective cohort study Patients with stage IV solid tumors who met the criteria of OMD (≤5 metastatic lesions, and or ≤2 organs) with performance status 0-2 were eligible; we studied disease characteristics and outcomes regarding local therapies of OMD.
Results
Two hundred and thirty-four patients with solid tumors met the criteria of OMD, 126 (53.8%) Patients received local therapies; surgery, Radiotherapy (RT), local ablative therapy (group I) and 108 (46.2%) Patients didn’t receive local therapy (group II). Comparing both groups, Group I: patients had significantly younger age, earlier initial TNM stage, higher rates of metachronous onset, symptomatic disease, soft tissue disease, single lesion and or single organ involvement and complete response, but lower rates of managed pulmonary OMD compared to group II. However, no significant association with specific primary cancer site, histological grade, molecular subtype, SUV activity level in PET/CT, type and number of systemic therapy lines, type of OMD (genuine vs. induced and repeated vs. de novo), cut of point of serum tumor markers or any subsequent delay of systemic treatment were noticed with local therapy (p value >0.05) and unexpectedly metastatic size of ≥ 3 cm was more amenable for local therapy (p value ≤0.05). Regarding survival, local therapy of OMD was associated with better PFS and OS: The mean OS in local therapy group was 64 months vs. 38 months in non local therapy patients and the median PFS was not reached in local therapy patients vs. 30 months in no local therapy patients. By multivariate regression analysis; local therapy for OMD is an independent prognostic factor for both PFS and OS.
Conclusions
For selected oligometastatic solid tumor patients, local therapy for OMD could improve PFS and OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract